Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pitavastatin + ezetimibe + valsartan
- Development stage
- Unknown
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
C2207 + JW0104 is a triple combination therapy being developed by JW Pharmaceutical for the management of patients with concurrent dyslipidemia and hypertension. The combination consists of JW0104, which is a fixed-dose combination of pitavastatin (an HMG-CoA reductase inhibitor) and ezetimibe (a cholesterol absorption inhibitor), and C2207, which is valsartan (an angiotensin II receptor blocker). Pitavastatin works by inhibiting hepatic cholesterol synthesis, while ezetimibe reduces the absorption of biliary and dietary cholesterol in the small intestine. Valsartan manages hypertension by selectively blocking the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion. This multi-mechanism approach aims to simplify treatment regimens and improve patient compliance in managing cardiovascular risk factors.
- Other names
- pitavastatin/ezetimibe + valsartan
02
Targets
NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on pitavastatin + ezetimibe + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pitavastatin + ezetimibe + valsartan.